verapamil has been researched along with Adenoma, Prolactin-Secreting, Pituitary in 4 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Verapamil stimulation test was previously investigated as a tool for differential diagnosis of hyperprolactinemia, but with conflicting results." | 7.76 | Verapamil stimulation test in hyperprolactinemia: loss of prolactin response in anatomic or functional stalk effect. ( Dagdelen, S; Usman, A, 2010) |
| "To describe a patient with an incidental pituitary lesion who experienced verapamil-induced hyperprolactinemia." | 7.69 | Verapamil-induced hyperprolactinemia complicated by a pituitary incidentaloma. ( Aron, DC; Dombrowski, RC; Romeo, JH, 1995) |
| "We studied the effect of acute administration of the calcium-channel blocker verapamil (VER) in 27 patients with tumoral hyperprolactinemia ([THPRL] prolactinomas and pseudoprolactinomas)." | 5.09 | Verapamil acute administration: a new dynamic test in hyperprolactinemic states. ( Barbaro, D; Bombara, M; Carnesecchi, C; Faggionato, F; Falciani, C; La Gioia, A; Loni, G; Palla, A; Pallini, S, 1999) |
| "Verapamil stimulation test was previously investigated as a tool for differential diagnosis of hyperprolactinemia, but with conflicting results." | 3.76 | Verapamil stimulation test in hyperprolactinemia: loss of prolactin response in anatomic or functional stalk effect. ( Dagdelen, S; Usman, A, 2010) |
| "To describe a patient with an incidental pituitary lesion who experienced verapamil-induced hyperprolactinemia." | 3.69 | Verapamil-induced hyperprolactinemia complicated by a pituitary incidentaloma. ( Aron, DC; Dombrowski, RC; Romeo, JH, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dagdelen, S | 1 |
| Usman, A | 1 |
| Knoepfelmacher, M | 1 |
| Villares, SM | 1 |
| Nicolau, W | 1 |
| Germek, OO | 1 |
| Lerário, AC | 1 |
| Wajchenberg, BL | 1 |
| Liberman, B | 1 |
| Dombrowski, RC | 1 |
| Romeo, JH | 1 |
| Aron, DC | 1 |
| Barbaro, D | 1 |
| Faggionato, F | 1 |
| Pallini, S | 1 |
| Carnesecchi, C | 1 |
| Palla, A | 1 |
| Bombara, M | 1 |
| Falciani, C | 1 |
| La Gioia, A | 1 |
| Loni, G | 1 |
1 trial available for verapamil and Adenoma, Prolactin-Secreting, Pituitary
| Article | Year |
|---|---|
Verapamil acute administration: a new dynamic test in hyperprolactinemic states.
Topics: Administration, Oral; Calcium Channel Blockers; Chemistry, Pharmaceutical; Humans; Hyperprolactinemi | 1999 |
3 other studies available for verapamil and Adenoma, Prolactin-Secreting, Pituitary
| Article | Year |
|---|---|
Verapamil stimulation test in hyperprolactinemia: loss of prolactin response in anatomic or functional stalk effect.
Topics: Adult; Biomarkers; Case-Control Studies; Diagnosis, Differential; Female; Humans; Hyperprolactinemia | 2010 |
Calcium and prolactin secretion in humans: effects of the channel blocker, verapamil, in the spontaneous and drug-induced hyperprolactinemia.
Topics: Adult; Calcium; Female; Humans; Hyperprolactinemia; Male; Prolactin; Prolactinoma; Sulpiride; Thyrot | 1994 |
Verapamil-induced hyperprolactinemia complicated by a pituitary incidentaloma.
Topics: Aged; Calcium Channel Blockers; Erectile Dysfunction; Humans; Hyperprolactinemia; Magnetic Resonance | 1995 |